# Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

> **NCT06719024** · PHASE2,PHASE3 · RECRUITING · sponsor: **Hospital Authority, Hong Kong** · enrollment: 20 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Ruxolitinib Cream 1.5%
- **DRUG:** Aqueous cream

## Key facts

- **NCT ID:** NCT06719024
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2025-06-16
- **Final completion:** 2026-01-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719024, "Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06719024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*